Trinity Biotech Plc Financials

Trinity Biotech Plc (TRIB) reported $61.6M in total revenue for fiscal year 2024. This represents a 8.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Trinity Biotech Plc (TRIB) revenue grew by 8.3% year-over-year, from $56.8M to $61.6M in fiscal year 2024.

No, Trinity Biotech Plc (TRIB) reported a net income of -$31.2M in fiscal year 2024, with a net profit margin of -50.7%.

Trinity Biotech Plc (TRIB) had a net profit margin of -50.7% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

Trinity Biotech Plc (TRIB) generated -$4.6M in free cash flow during fiscal year 2024. This represents a 62.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Trinity Biotech Plc (TRIB) generated -$4.2M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

Trinity Biotech Plc (TRIB) had $103.3M in total assets as of fiscal year 2024, including both current and long-term assets.

Trinity Biotech Plc (TRIB) invested $405K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

Trinity Biotech Plc (TRIB) had 359M shares outstanding as of fiscal year 2024.

Trinity Biotech Plc (TRIB) had a current ratio of 1.28 as of fiscal year 2024, which is considered adequate.

Trinity Biotech Plc (TRIB) had a debt-to-equity ratio of -3.94 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

Trinity Biotech Plc (TRIB) had a return on assets of -30.2% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2024 data, Trinity Biotech Plc (TRIB) had $5.2M in cash against an annual operating cash burn of $4.2M. This gives an estimated cash runway of approximately 15 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Trinity Biotech Plc (TRIB) has negative shareholder equity of -$35.2M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Trinity Biotech Plc (TRIB) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Trinity Biotech Plc (TRIB) has an earnings quality ratio of 0.13x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.